BioXcel Therapeutics Inc (BTAI) Expected to Post Earnings of -$0.26 Per Share

Equities research analysts expect BioXcel Therapeutics Inc (NASDAQ:BTAI) to report ($0.26) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for BioXcel Therapeutics’ earnings. The firm is expected to announce its next earnings report before the market opens on Friday, November 9th.

According to Zacks, analysts expect that BioXcel Therapeutics will report full year earnings of ($1.12) per share for the current fiscal year. For the next financial year, analysts anticipate that the firm will report earnings of ($1.94) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover BioXcel Therapeutics.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Wednesday, August 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.13.

A number of equities research analysts recently issued reports on BTAI shares. Zacks Investment Research upgraded shares of BioXcel Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Tuesday, August 14th. Canaccord Genuity reiterated a “buy” rating and set a $21.00 target price on shares of BioXcel Therapeutics in a research report on Friday, August 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of BioXcel Therapeutics in a research report on Wednesday, August 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $18.67.

A number of large investors have recently modified their holdings of the business. Point72 Asset Management L.P. grew its holdings in BioXcel Therapeutics by 10.7% during the 2nd quarter. Point72 Asset Management L.P. now owns 65,809 shares of the company’s stock worth $605,000 after acquiring an additional 6,358 shares during the last quarter. Creative Planning bought a new stake in BioXcel Therapeutics during the 3rd quarter worth about $102,000. BlackRock Inc. bought a new stake in BioXcel Therapeutics during the 2nd quarter worth about $137,000. Artemis Investment Management LLP grew its holdings in BioXcel Therapeutics by 1.3% during the 3rd quarter. Artemis Investment Management LLP now owns 1,254,853 shares of the company’s stock worth $9,700,000 after acquiring an additional 16,358 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in BioXcel Therapeutics during the 1st quarter worth about $316,000. 23.90% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BioXcel Therapeutics stock traded down $0.15 during mid-day trading on Friday, reaching $5.90. 82,000 shares of the stock were exchanged, compared to its average volume of 43,969. BioXcel Therapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $14.79.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

See Also: Google Finance Portfolio Workaround

Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply